Dasatinib in recurrent glioblastoma: failure as a teacher

Affiliations

Editorial

David Schiff et al. Neuro Oncol. 2015 Jul.

. 2015 Jul;17(7):910-1.

doi: 10.1093/neuonc/nov086. Epub 2015 May 10.

¹ University of Virginia Neuro-Oncology Center, Charlottesville, Virginia (D.S.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.S.).

No abstract available

Comment on

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, Youssef E, Wagner H, Won M, Mehta MP. Lassman AB, et al. Neuro Oncol. 2015 Jul;17(7):992-8. doi: 10.1093/neuonc/nov011. Epub 2015 Mar 10. Neuro Oncol. 2015. PMID: 25758746 Free PMC article. Clinical Trial.

1. Wick W, Weller M, Weiler M, et al. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011;13(6):566–579. - PMC - PubMed
1. de Groot J, Milano V. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol. 2009;95(2):151–163. - PubMed
1. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12(16):4899–4907. - PubMed
1. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012;33(3):122–128. - PMC - PubMed
1. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470–480. - PubMed